
    
      Volunteers will randomly receive either the commercial oral tablet 100 mg ImitrexÂ® or 75 mg
      Omexa sublingual tablet under fasted conditions. One week following the first administration,
      the volunteers will receive the alternative treatment.

      Blood samples will be collected at each visit before drug administration and at 5, 15, 30,
      45, 60, 90, 120, 240, 360 and 480 min after drug administration, in order to characterize the
      drug's absorption and pharmacokinetics, as well as to evaluate Omexa formulation safety.
    
  